Artificial intelligence has moved past its experimental phase in enterprise software; the question for 2026 is no longer whether to use it, but where and how. At the same time, the gap between marketing language and real capability has never been wider. While an AI label gets stamped on every product page, the applications that genuinely help organizations are concentrating in specific areas. In this article we look at the trends shaping enterprise software in 2026 — and share where Afinitem's own R&D agenda fits into the picture.
From generative AI to reasoning
The first wave of generative models impressed with writing and summarizing; for enterprise decision-making, however, the real value lies in a model's ability to reason step by step. Reasoning-focused models make it traceable how a conclusion was reached, answering the trust problem that has been the biggest obstacle to corporate adoption. In fields like healthcare, where mistakes are costly, systems that show their reasoning are overtaking systems that merely answer. Afinitem has a project moving in exactly this direction: our large language model work focused on Turkish natural language processing and medical reasoning, where development continues on symptom analysis, reasoning and diagnosis suggestions. It is not a released product yet — but its direction matches where the industry is heading.
Domain-focused intelligence over general models
Another clear trend of 2026 is the shift from do-everything giant models toward focused systems that go deep on one domain's data. A general chat model can look impressive, but interpreting a laboratory result, catching a deviation on a production line or supporting a risk assessment requires models trained on the field's own data with clearly drawn boundaries. One of our R&D projects in this space, FNN Blood Analysis, aims at automatic analysis of blood test results using Feedforward Neural Network and deep learning models. The project is in development, and we are deliberate about the distance still to be covered before anything approaches clinical use.
What it means for organizations: preparation, not hype
This picture tells organizations two things. First, the precondition for extracting value from AI is orderly, accessible data — no model can rescue an organization whose records are scattered. Second, the right question is not which AI product to buy, but in which process a layer that supports human judgment would actually help. Organizations that avoid inflated promises and advance through small pilots will be the ones that turn this technology into lasting value rather than a line item in last year's budget.
Responsibility deserves equal attention. A setup in which AI output never has the final word but passes through human approval both prevents errors from spreading and builds employee trust in the technology step by step. In sensitive domains such as health data, knowing what a model does not know is as valuable as knowing what it does. The winners of 2026 will not be those who deploy the largest model, but those who embed the technology into their own processes with the most care.
At Afinitem, our Reasoning LLM and FNN Blood Analysis projects represent our research-side contribution to this shift. If you would like to discuss your own AI agenda or follow our work more closely, get in touch — we are glad to share what we are learning.